1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Merck & Co’s TROP2 Partner Trumpets Phase III Success In TNBC

Kelun Planning China Filings

 
• By Kevin Grogan

Merck & Co's antibody-drug conjugates pact with Kelun is progressing well and the lead candidate of the pact, the TROP2-targeting candidate codenamed SKB264/MK-2870, has significantly improved progression-free survival in triple-negative breast cancer patients in a late-stage trial in China.

• Source: Shutterstock

Merck & Co., Inc.'s advances into the antibody-drug conjugate space through its partnership with Sichuan Kelun Pharmaceutical Co Ltd. continue to bear fruit with the Chinese biotech heralding success in a late-stage study for the leading compound in the pact, MK-2870/SKB264, in the treatment of triple-negative breast cancer (TNBC).

Kelun has announced that an independent data monitoring committee has concluded an interim analysis of data from a Phase III trial of MK-2870/SKB264, which targets TROP2, and declared that the trial met the primary endpoint of significantly improving progression-free survival compared with standard chemotherapy in patients with advanced or metastatic TNBC who have failed at least second-line therapy

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

iTeos/GSK To Terminate Collaboration After TIGIT Trials Flop

 
• By Alaric DeArment

Belrestotug is the latest anti-TIGIT candidate to fail to meet expectations. iTeos said it will pursue strategic alternatives.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe